WASHINGTON — The Food and Drug Administration’s top compounding staffer, Julie Dohm, is leaving the agency effective March 29.
Since 2016, Dohm has steered the FDA through the contentious implementation of the compounding law passed by Congress in the wake of a 2012 meningitis outbreak that killed 64. During Dohm’s tenure, FDA released nearly two dozen far-reaching policies, conducted more than 400 inspections of compounders, and took a number of compounding pharmacies to court for alleged violations of the law.
About the Author Reprints
